• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

Single dose mass vaccination against COVID-19 is linked with reductions in hospital admissions

byCyrus AyubchaandTeddy Guo
May 12, 2021
in Infectious Disease, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. The initial doses of the Pfizer and AstraZeneca vaccines were 91% and 88% efficacious in reducing COVID-19 hospitalizations one month after vaccination.

2. Combined vaccine efficacy of the Pfizer and AstraZeneca in preventing hospital admission due to COVID-19 among those aged 80 years and older was approximately 83%.

Evidence Rating Level: 2 (Good)

Study Rundown: At the time of this publication, the COVID-19 pandemic continues to burden healthcare systems worldwide. In many countries, the demand for vaccines surpasses the available supply. To work around the low vaccine availability, some regions have opted for a first-dose mass vaccination program with a delayed second dose rather than the recommended two-dose regimen with vaccines given three weeks apart. However, the long-term efficacy of various COVID-19 vaccines after a single dose is still largely unknown. In this observational study, the effectiveness of a first dose of either the BNT162b2 mRNA (Pfizer-BioNTech) or ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccine in preventing hospital admissions was investigated. This study found that the Pfizer and AstraZeneca vaccines were approximately highly effective in reducing COVID-19-related hospitalizations at approximately one month after the first dose. Overall, this study reports the effectiveness of a single dose mass vaccination program in over one million vaccinated individuals. Nevertheless, the observational nature of this study inclines the results to be confounded by ecological and temporal effects.

Click to read the study in the Lancet

Relevant Reading: Mass-Vaccination Sites — An Essential Innovation to Curb the Covid-19 Pandemic 

RELATED REPORTS

The 2 Minute Medicine Podcast Episode 55

The Scan by 2 Minute Medicine®: Triple Attack Against Endometriosis, Vaccines and Autism, Revisited, The Final Frontier of Human Health, and Eating Well to Live Better:

The 2 Minute Medicine Podcast Episode 54

In-Depth [prospective cohort]: This study utilized a prospective cohort structure to enroll 1,331,993 subjects between Dec 8, 2020, and Feb 22, 2021. Notably, all those having previously tested positive for COVID-19 were excluded. Treatment exposure was defined as receiving a single dose of either the BNT162b2 mRNA (Pfizer-BioNTech) or ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccine between Dec 8, 2020, and Feb 22, 2021. The main outcome was hospital admissions due to COVID-19, or any hospital admission within 28 days of a positive COVID PCR test between Dec 8, 2020, to Feb 22, 2021. Cox models and Poisson regressions were utilized with respective covariates (e.g. comorbidity, smoking status, socioeconomic status etc.); further analyses were utilized to assess certain age groups (18-64, 65-79, >80 yo). A downturn in admissions was observed before the vaccination rollout however further modeling attempted to assess the isolated effects. Vaccine effect at 28-34 days after vaccination led to a reduction in COVID-19 hospital admissions (Pfizer 91% [95% CI 85-94], AstraZeneca 88% [95% CI 75-94]). In a pooled analysis of both vaccines, similar findings were observed among patients aged 18-64 years (92%, 95% CI 82-97), 65-79 years (93%, 95% CI 73-98), and those aged 80 years or older (83%, 95% CI 72-89).

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: astrazenecabnt162b2ChAdOx1ChAdOx1 nCoV-19 vaccineChAdOx1 vaccinecovidCOVID-19 antibodiescovid-19 diagnosiscovid-19 infectionCOVID-19 Vaccinemass vaccinationpfizervaccinationvaccine
Previous Post

Routine urinary tract cancer testing among all patients with microhematuria has low diagnostic yield

Next Post

#VisualAbstract: Convalescent plasma transfusion provides mortality benefit in early COVID-19 disease stage

RelatedReports

The 2 Minute Medicine Podcast Episode 15
2MM Podcast

The 2 Minute Medicine Podcast Episode 55

April 5, 2025
The Scan by 2 Minute Medicine: The Role of Virtual Reality in Pain Management, WHO’S controversial diagnosis on gaming addictions, the TikTok ban and psychology of doom scrolling, and the risk of smart devices replacing annual checkups
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Triple Attack Against Endometriosis, Vaccines and Autism, Revisited, The Final Frontier of Human Health, and Eating Well to Live Better:

April 1, 2025
The 2 Minute Medicine Podcast Episode 15
2MM Podcast

The 2 Minute Medicine Podcast Episode 54

March 21, 2025
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Measles Outbreak, Tariffs and Healthcare, Pope’s Pneumonia, and Removing Fluoride from Water:

March 18, 2025
Next Post
#VisualAbstract: Sonelokimab showed significant clinical benefit over placebo in patients with plaque psoriasis

#VisualAbstract: Convalescent plasma transfusion provides mortality benefit in early COVID-19 disease stage

Comprehensive home geriatric assessment provides similar outcomes as hospital admission

#VisualAbstract: Adjuvant pembrolizumab does not reduce health-related quality of life in patients with stage III melanoma

#VisualAbstract: Lobaplatin-based induction chemotherapy is safe and efficacious for patients with advanced nasopharyngeal carcinomas

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Obicetrapib Reduced LDL Cholesterol in Patients at High Cardiovascular Risk
  • St. Louis hospital-based violence intervention program did not significantly affect reinjury outcomes
  • Glucagon-like peptide-1 receptor agonists may increase risk of reflux in patients with type 2 diabetes
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.